This site requires flash 8 You currently do not have the necessary Macromedia Flash plug-in to view this page
Click here to download the Macromedia Flash plug-in
Exenatide is the first in a new class of agents called incretin mimetics. Incretins are endogenous compounds, such as glucagon-like peptide-1 (GLP-1), that improve glycemic control once released into the circulation via the gut.
Exenatide is a synthetic form of exendin-4, a 39-amino acid peptide isolated from the venom of the Gila monster lizard (Heloderma suspectum, Helodermatidae). Exenatide is an incretin mimic that acts as an agonist at the glucagon-like peptide 1 receptor to enhance insulin secretion in the presence of raised glucose concentrations; Exenatide also suppresses inappropriate glucagon secretion and slows gastric emptying.
Exenatide is manufactured and marketed by Amylin Pharmaceuticals under the brand names BYETTA™ ®.
Exenatide is the first in a new class of antihyperglycemic agents called incretin mimetics, that mimics the enhancement of glucose-dependent insulin secretion and several other antihyperglycemic actions of incretins. Incretins, such as glucagon-like peptide-1 (GLP-1), enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following release into circulation from the gut. Exenatide mimics the enhancement of glucose-dependent insulin secretion and other antihyperglycemic actions of incretins. The exenatide peptide has 53% amino acid similarity to mammalian GLP-1 and has a 3000-fold greater potency for glucose lowering in vivo. Exenatide binds and activates the human GLP-1 receptor site in vitro. Occupation of the GLP-1 receptor site by exenatide results in an increase in both glucose-dependent synthesis of insulin, and in vivo secretion of insulin from pancreatic beta cells in the presence of elevated glucose. Increased synthesis and release of insulin occurs via mechanisms involving cyclic AMP and/or other intracellular signaling pathways.
Exenatide is given by subcutaneous injection in an initial dose of 5 micrograms. Exenatide is supplied in a 250mcg/1ml solution for injection.
General data on Exenatide Active Pharmaceutical Ingredients
Molecular Formula: C184H282N50O60S CAS Registry: 141758-74-9 ATC: A10BX04
TAPI's Exenatide Active Pharmaceutical Ingredient
TAPI's Exenatide Active Pharmaceutical Ingredient is produced in Assia Industries Limited –Teva Tech site in Beer Sheva, Israel.
Over the last 15 years TAPI has developed the expertise in developing and commercialization of peptide Active pharmaceutical ingredients, such as Exenatide. With numerous worldwide approvals, we are continuously driven by the goal of helping our customers achieve success-and ultimately approval for their peptide APIs. We offer grams to hundred kilograms production capabilities, comprehensive technology platform including solid phase, solution phase, and hybrid approach, combined with a well established scientific experience, enabling the implementation of efficient process aimed for high quality product. We offer Custom Synthesis and Manufacturing services on peptide Active pharmaceutical ingredients.
TAPI provide full service on Exenatide and other APIs in our portfolio. Our local sales offices provide full information on our product, regulatory compliance and documentation on Exenatide. Contact us today for further inquiries and samples availability information for TAPI's Exenatide.
Product exploitation, including development, sales and offer for sale are performed where permissible by patent law. This presentation is not and should not constitute an offer for sale in territories where it is not permitted by law. In USA Products that Currently on Patent are available for R&D Use in Accordance with 35 USC §271 (e) (1).
*TAPI stands for Teva's Active Pharmaceutical Ingredients
